Originally published in the BioPharma Reporter on March 15, 2022
The Massachusetts Biotechnology Council (MassBio) has just revealed the five emerging biotech companies chosen to participate in the spring 2022 cohort of its accelerator program.
The initiative, called MassBioDrive, looks to harness the power of the organization’s global life sciences network to help new founders launch their startups more effectively and efficiently.
“The science and technologies that these companies are pioneering represent the future of the life sciences. From simplifying CAR-T production to developing new therapeutics for acute kidney injury patients, the MassBioDrive spring cohort has enormous potential to address pressing unmet medical needs,” said Joe Boncore, CEO of MassBio.